Cornea

This year was brimming with advancements in eye care.

According to Robert Latkany, MD, understanding the causes and recognizing these diagnostic features are essential for effective treatment.

Trending topics and milestone stories from our year in ophthalmology.

Highlights from the year, courtesy of our colleagues at Ophthalmology Times

Trending topics and milestone stories from our year in ophthalmology

Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.

Our top 10 print stories highlight the core content concepts we explored this year

Low-level light therapy for dry eye disease and chalazion

In an interview with Ophthalmology Times, clinical trial investigator Zaina Al-Mohtaseb MD, noted the CLARA Phase 1/2 trial demonstrated the safety, efficacy, and simplicity of corneal endothelial cell injection therapy with a rho kinase inhibitor, offering a less invasive alternative to traditional corneal transplantation for treating corneal edema.

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

Research data published earlier this year could help clinicians gain a better understanding of what to look for in a specular microscope, and how to interpret inter- and intradevice repeatability results in a way that benefits their existing practice framework.

VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, is advancing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive treatment for infectious keratitis, leveraging light-based technology and addressing antimicrobial resistance to improve outcomes for patients with severe eye infections globally.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

The authors analysed severity and frequency of ocular pain among patients with DED living in altitudes above 2,500 meters during the COVID-19 pandemic

The incidence was comparable to that of daily wear soft contact lenses.

The incidence was comparable to that of daily wear soft contact lenses

A Q&A with PPP Committee Cornea/External Disease Panel member Daniel S. Choi, MD.

A discussion with Shigeru Kinoshita, MD, PhD; and Edward J. Holland, MD.

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The therapy improved vision, reduced central corneal thickness, and demonstrated strong safety, offering an alternative to corneal transplants.

Assessing two devices in a real-world setting

Investigators from Bergen, Norway, and Cleveland, Ohio, collaborated on the predictive model

Research indicates suppressive valacyclovir could help patients avoid keratitis and iritis flare-ups

Corneal confocal microscopy, semaglutide therapy offer treatment options

The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers